Centessa has been formed as a biotech conglomerate with $250m in funding following a ten-way merger, including multiple spinouts.

MIT’s cancer and infectious disease therapy spinout has added $40m to a round that will support the progression of its lead asset into the clinic.

Xfund is among the backers of a $17m round for ImmuneID, which has been set up to commercialise research from Harvard University and Johns Hopkins University.

Rogue has achieved a first close for its fourth fund, although it is as-yet unclear whether Oregon State University is again an investor.

Washington University in St Louis joined a consortium of investors that provided $130m in series B financing to the commercial space station developer.

The Johns Hopkins University spinout’s latest funding will go toward further developing its lead candidate, VTA-110, for muscular dystrophy treatments.

Caltech spinout Talis Biomedical has raised more than $220m in an initial public offering on the Nasdaq Global Market.

NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.

The vehicle charging technology developer, spun out of UC Irvine, has now raised $191m in total.

The gas-to-hydrogen technology developer bagged $11.5m in funding to commercialise technology developer at UC Santa Barbara.